REPLIMUNE GROUP, INC. Increase (Decrease) in Other Noncurrent Assets
REPLIMUNE GROUP, INC. (REPL) reported Increase (Decrease) in Other Noncurrent Assets of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-06-29
- REPLIMUNE GROUP, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $0.00.
- REPLIMUNE GROUP, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-03-31 was $0.00.
- REPLIMUNE GROUP, INC. increase (decrease) in other noncurrent assets for the quarter ending 2024-03-31 was $0.00.
- REPLIMUNE GROUP, INC. increase (decrease) in other noncurrent assets for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- REPLIMUNE GROUP, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was $1.20M.
- REPLIMUNE GROUP, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $0.00 10-K · filed 2026-06-29 | |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-03 | ||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $1.20M 10-K · filed 2026-06-29 | |
| 2024-12-31 | $1.20M 10-Q · filed 2026-02-03 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $0.00 10-K · filed 2025-05-22 | |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |